$CLVS maybe it’s a good a idea to put all the information together for the last months: - Institutions loading during the last two weeks - FDA granted an expedited review for Rubraca m-CRPC- PDUFA 15-May-2020 ( approval in every moment as FDA needs to review the new clinical data and safety updates Of the dossier) - Last Quarter reported 354 M in cash anticipated cash until 2021 = no need for more offerings. - Increased net product revenue for guidance to 141-147 M. - New NDA for FAP- 2286 to be filled by 2H of 2020 I’m not worried about the stock price guys....missed something?
  • 7
  • 2